Skip to content

Cooling Via Cryogenx Body Cooling Device

Efficacy of Post Exercise Heat Stress Cooling Via Cyrogenx Body Cooling Device

Status
Not yet recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06517147
Enrollment
12
Registered
2024-07-24
Start date
2024-09-01
Completion date
2025-07-31
Last updated
2024-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Temperature Changes

Brief summary

The aim of this project is to test the rate of cooling following exercise in the heat utilising the CRYOGENX Cryosuit device i) against passive cooling, and ii) to quantify the rate of cooling and compare this rate with established cooling intervention thresholds i.e. -0.11 to 0.15°C.min-1. As this project is to determine the efficacy of the intervention in populations equivalent to sporting and military personnel, these aims will be tested in young (18-40 year old) healthy male and female participants whom participate in regular physical activity. As a commercially funded project, the experimental design implemented will closely replicate that of the independent investigation into the efficacy of the CAERvest® device.

Interventions

DEVICECryogenx cooling

During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.

DEVICERegular cooling

During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.

Sponsors

Brunel University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

The inclusion criteria are: Aged 18 - 40 years Free from known injury, illness and disease and regular use of medications other than oral contraceptives Undertake exercise training \>3 times per week for \ 30 minutes per session The

Exclusion criteria

are: Pregnant Previous history of neuromuscular fatigue Previous history of heat intolerance

Design outcomes

Primary

MeasureTime frameDescription
Core (rectal) temperature12 monthsThe rate of change of core temperature during cooling will be calculated from realtime data

Contacts

Primary ContactOliver R Gibson, PhD
oliver.gibson@brunel.ac.uk+44(0)1895 267957

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026